Neuropathology and Applied Neurobiology 43, 299-314 Effect of systemic transplantation of bone marrow-derived mesenchymal stem cells on neuropathology markers in APP/PS1 Alzheimer mice Aims: Mesenchymal stem cells (MSC) have recently attracted interest as a potential basis for a cell-based therapy of AD. We investigated the putative immunemodulatory effects in neuroinflammation of systemic transplantation of MSC into APP/PS1 transgenic mice. Methods: 10 6 MSC were injected into APP/PS1 mice via the tail vein and histological analysis was performed for microglia and amyloid (pE3-Ab) plaque numbers, glial distribution and pE3-Ab plaque size. In addition, a biochemical analysis by qPCR for proinflammatory, chemoattractant and neurotrophic factors was performed. Results: MSC are associated with pE3-Ab plaques. The effects of transplantation on microglia-associated pathology could be observed after 28 days. Animals showed a reduction in microglial numbers in the cortex and in microglia size. Gene expression was reduced for TNF-a, IL-6, MCP-1, and for NGF, in MSC recipients. Also, we investigated for the first time and found no changes in expression of IL-10, CCR5, BDNF, VEGF and IFNc. PTGER2 expression levels were increased in the hippocampus but were reduced in the cortex of MSC recipients. While there were no transplant-related changes in pE3-Ab plaque numbers, a reduction in the size of pE3-Ab plaques was observed in the hippocampus of transplant recipients. Conclusion: This is the first study to show reduction in pE3-Ab plaque size. pE3-Ab plaques have gained attention as potential key participants in AD due to their increased aggregation propensity, the possibility for the initial seeding event, resistance against degradation and neurotoxicity. These findings support the hypothesis that MSC-transplants may affect AD pathology via an immune-modulatory function that includes an effect on microglial cells.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disease marked histopathologically by amyloid b aggregations, neurofibrillary tangles and neuronal impairment finally leading to memory impairments [1] . Some reports suggest the role of oxidative and inflammatory stress together with microglia changes preceding the onset of clinical and pathological AD symptoms [2] [3] [4] [5] .
Mesenchymal stem cells (MSC) have recently attracted interest as a potential basis for a cell-based Alzheimer therapy [6] [7] [8] but apart from their clinical potential their mechanism of action has yet to be ascertained.
One potential approach is to study the impact of MSC on microglia, the resident macrophages of the brain. Microglia show early signs of dysfunction in AD [9] . The microglia can either be neuroprotective or neurotoxic depending on the secretion profile and surface marker expression [10, 11] . Activated microglia secrete a variety of pro-inflammatory cytokines including interleukin-6 (IL-6) and tumour necrosis factor-a (TNF-a), which induce neuroinflammation [12] . Microglia also participate in the recruitment of cells into the brain and to AD-associated amyloid plaques through chemokine secretion, such as monocyte chemotactic protein-1 (MCP-1) [13] [14] [15] . However, microglia are also known to produce neurotrophic factors such as brain-derived neurotrophic factor (BDNF), neuronal growth factor (NGF) and vascular endothelial growth factor (VEGF/A), providing trophic support to neurones.
Previous studies in AD mice have been performed using intracranial application of MSC. These studies showed promising results, however, they had several drawbacks including the use of human cells in an animal model and an invasive intra-cerebral transplantation delivery method [16, 17] . There have at present been no studies using systemic MSC injections. One study used systemic injections, however, the cells used were described as bone marrow-derived cells and not described or characterized as MSC. In addition, in the same study the animals were also irradiated [18] .
In summary this demonstrated the need for a study that systemically applied MSC via injections to an AD mouse model. Also for translational purposes we were interested in testing a minimally invasive method of cell administration using systemic injection.
We found that MSCs were able to migrate into the brain and reduced the amount of middle sized pE3-Ab amyloid plaques. Microglial numbers were not changed, however, we found that microglia and astrocyte activation levels were decreased. In addition, the expression of several important inflammatory markers were reduced in AD mice transplanted with MSC in comparison to control animals.
Material and methods

Animals
Transgenic mice overexpressing human amyloid precursor protein (APP KM670/671NL ) and presenilin-1 (PS1   L166P   ) under Thy-1 promoter control (age 12-15 months) were obtained from University of Leipzig (Prof. Bechmann) and the German Centre for Neurodegenerative Diseases (Prof. M. Jucker,) T€ ubingen [19] . C57BL/6 from the MEZ of the University of Leipzig or Charles River were used as a source for bone marrow-derived MSC. GFP-transgenic mice (12 weeks) were from the Paul Flechsig Institute for Brain Research, University of Leipzig. The experiments were approved by the local Animal Welfare Committee of the University of Leipzig and by the local governmental authorities (Landesdirektion Sachsen, permit numbers T70/12, T72/13, TVV 07/08).
MSC preparation
Bone marrow was cultured in DMEM low glucose (Gibco, 21885-108) with 10% foetal calf serum (Hyclone, SV30160.03) and 1% penicillin/streptomycin (Gibco, 15070-063). Briefly, mouse bone marrow cells were obtained by centrifugation from tibiae and femurae and cultured according to the methods of Dobson et al. [20] . MSC were isolated by the methods of Sekiya et al. [21] . MSC were passaged when they were 70% confluent using trypsin (Trypsin-EDTA 0.25% Gibco). Identity was confirmed by staining for MSC-specific markers (CD11 ) and mesodermal lineage differentiation (data see supplement). MSC were used for transplantations at passage 1-2.
sone (Sigma-Aldrich, D4902, Hamburg, Germany); 50 lg/ ml ascorbic acid 2-phosphate (Sigma-Aldrich, A8960-5G). Medium was changed every 2 days. After 14 days qualitative analysis was done: Cells were fixed with 70% Ethanol (VWR445363) and stained for alkaline phosphatase with Fast Red (0.2 M Tris (Sigma-Aldrich 459836); 1 mg/ml Fast Red (Sigma-Aldrich 51503); 50 lg/ ml naphtol phosphate AS-BI (Sigma-Aldrich) for 1 h.
Adipogenic differentiation
Cells were seeded at 2 9 10 4 cells/1. MSC were then analysed using the personal flow cytometry system (Beckman Coulter, Krefeld, Germany).
Transplantation
For histological analysis 10 6 MSC in 150 ll NaCl from female/male donors were injected per male animal (day 7 n = 3 and day 28 n = 4) via the tail vein and for biochemistry analysis 10 6 MSC in 150 ll NaCl from male donors were injected into female recipients (day 28, n = 3). The control mice were injected with 150 ll NaCl (n = 11). After 7 or 28 days animals were sacrificed and the organs isolated for biochemical or histological analysis. In some cases we used MSC from eGFP transgenic mice.
Tissue preparation
Mice were perfused 7 and 28 days after transplantation. For biochemistry, mice were perfused transcardially after death with 0.9% NaCl. Brains were removed, divided into five regions (hippocampus, cortex, cerebellum, brain stem and olfactory bulb) and stored in peqGOLD TriFast TM (PeqLab, 30-2040, Erlangen, Germany) at À80°C until further use as well as pieces of nine peripheral organs.
For histology, mice were perfused transcardially after death with 0.9% NaCl followed by fixative containing 4% paraformaldehyde and 0.1% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4). Brains were removed and immersion-fixed overnight in the same fixative at 4°C. Brains were cryoprotected in 30% sucrose in 0.1 M phosphate buffer (pH 7.4) with 0.1% sodium azide, cut into 40 lm slices with a cryomicrotome in frontal plane. Slices were collected in 0.1 M phosphate buffer (pH 7.4) with 0.1% sodium azide. All slices used were incubated overnight at 4°C in blocking solution and primary antibody. The primary antibodies used were: anti-Iba-1 (rabbit, 1:600; Wako), anti-pyroglutamate-beta amyloid (pE3-Ab) (mouse, 1:500; Synaptic Systems, Göttingen, Germany) and anti-GFAP antibody (rabbit, 1:700; DAKO, Hamburg, Germany). After washing three times in PBS-T, the biotinylated secondary donkey-anti-mouse IgG antibody (1:1000; Dianova) or donkey-anti-rabbit IgG antibody (1:1000; Dianova) was applied for 1 h in solution containing 50% blocking solution and 50% PBS-T. Sections were washed three times in PBS-T and incubated in peroxidase-coupled extravidin (1:2000, Sigma-Aldrich, E2886) for 1 h in 1 part blocking solution and two parts PBS-T, followed by washing and incubation with 0.05M Tris-buffer pH 8 for 5 min. Subsequently, brains were placed in 10 ml 0.05M Trisbuffer (pH 8), 4 mg DAB and 5 ll 30% H 2 O 2 until a colour change was visible. For pE3-Ab staining diaminobenzidine with nickel ammonium sulphate (Sigma-Aldrich, 7785-20-8) enhancement (DABNi) was used. A solution of 10 ml Tris-buffer with 40 mg of nickel ammonium sulphate was prepared followed by the addition of 4 mg DAB. After that 5 ll 30% H 2 O 2 was added to the mixture. Brain slices were incubated in DABNi for 30 min. Sections were finally washed, placed on glass slides, dried and mounted with entellan in toluol (Merck, 108323, Darmstadt, Germany).
Immunohistochemistry
Immunofluorescence for microglia was carried out with rabbit anti-Iba-1 (WAKO, 1:500, 019-19741) overnight, followed by secondary antibody donkeyanti-rabbit Cy3 (Dianova, 1:250, 711-165-152) for 1 h. Slices for LSM double fluorescence images ( Fig. 1) were stained without immunohistochemical enhancement for immigrated eGFP + MSC.
Immunohistochemistry for astrocytes was performed as followed: brain slices were mounted on the cover slides. Autofluorescence quenching was performed by incubating the brain slices with Image-IT (Life Technology, I36933) for 30 min. After that, brain slides were washed twice with PBS followed by incubation with blocking solution for 30 min. Then, rabbit anti-GFAP antibody (1:700; DAKO, Z033429-2) in blocking solution was added to the brain slices and incubated over night at 4°C. Next, brain slices were washed three times with PBS and incubated with donkey-anti-rabbit Northern Lite 557 (1:200; R&D, NL004) for 1 h followed by washing three times with PBS. The nucleus was stained with 0.5 lM Sytox Green (Life Technology, S7020) for 30 min. Brain slices were mounted using ProLong â Gold Antifade mounting medium (Molecular Probes, P36934, Eugene, OR, USA). Immunofluorescence for GFP was carried out with goat anti-GFP overnight, followed by secondary antibody donkey-anti-goat Cy2 (Dianova, 1:250, 705-225-147) for 1 h.
Thioflavin-S staining
Brain slices were incubated in 0.5% Thioflavin-S solution (Sigma, T1892-25G) for 5 min at room temperature. Sections were then washed with 70% ethanol followed by 50% ethanol. Each washing step was performed at room temperature for 5 min. After the ethanol washes, the sections were washed once with water for 5 min at room temperature. Sections were dried and mounted with entellan (VWR, 1079600500).
Microscopy and image processing
Tissue sections were examined with the Keyence BZ-9000 microscope equipped with a BZ-9000 Analyser software (Keyence Corporation, Itasca, IL, USA) for light and fluorescence microscopy. Haze reduction and white/black balance were used to process the images with minimal alterations to brightness, sharpness, colour saturation and contrast. Fluorescence labelling ( Fig. 1 ) was examined with a Zeiss confocal laser scanning microscope (LSM 510, Zeiss, Jena, Germany). For secondary Cy2-labelling (green fluorescence), an argon laser with 488-nm excitation was used and emission from Cy2 was recorded at 510-nm applying a lowrange band pass (505-550 nm). For secondary Cy3-labelling (red fluorescence), a helium-neon laser with 543-nm excitation was used and emission from Cy3 at 570 nm was detected applying a high-range band pass (560-615 nm). Photoshop CS2 (Adobe Systems, Mountain View, CA, USA) was used to process the images with minimal alterations to brightness, sharpness, colour saturation and contrast. 
Resident microglia and immigrated GFP + MSC 28 days after transplantation
Stereology
Microglia (Iba-1) and plaque (pE3-Ab) numbers were evaluated for the whole cortex and hippocampus using Zeiss Axio Imager microscope (Carl Zeiss) and quantified by Stereo Investigator 8 software (MBF Bioscience, Williston, VT, USA). The distance between each counting frame was 350 9 350 lm and a counting frame of 250 9 250 lm was used for counting microglia and plaques with 209 objective. Where the results were unclear a higher magnification (409 or 639) was used to distinguish cells residing below another.
Nine sections per animal, taken from beginning to the end of the cortex and hippocampus were examined, at a serial interval of every 10 slices, with a counting frame for the cortex~200 and hippocampus~70 per slice. The whole left cortex and hippocampus were counted and the numbers multiplied by 2 to cover both hemispheres.
Measurement of pyroglutamate-beta amyloid (pE3-Ab) plaque size
To determine the amyloid plaque size, pictures from the cortex (4-5 pictures) and hippocampus (3-4 pictures) were randomly taken from one slide of each animal. Analysis was performed in the anterior, middle and posterior hippocampus and cortex. Photos were taken at 209 objective with BZ-9000 Keyence microscope and analysis performed with BZ-II Analyser Software (Keyence). Plaque diameter was determined by measuring the distance between two opposite points at the plaque edge. A line was drawn from the beginning to the end of the plaque and diameter in lm was obtained for each plaque. The software automatically calculated the diameter based on the length of the drawn line.
Microglia covered area measurement
Microglia covered area was determined using Keyence BZ900 microscope and BZ-II Analyser Software (Keyence). Pictures of Iba-1-positive cells (microglia) were taken randomly in the cortex (5 pictures) and hippocampus (4 pictures) for every mouse. Analysis was performed using the Hybrid Cell Count software module in BZ-II Analyser Software. Settings for brightness and threshold were adapted and applied for all measurements. Brightness of Iba-1 fluorescence was manually set at a maximum threshold where background was barely present. Threshold was established independently for each mouse. Areas located on corners and holes were manually excluded to reduce noise in the analysis. After setting the brightness parameters Iba-1 + covered area was obtained for every picture. Covered area was calculated as the mean of all images determined for every mouse.
Astrocyte covered area measurement
Analysis of the total area covered by astrocytes labelled with GFAP antibody was performed in the cortex and hippocampus. Single pictures of the whole brain area were taken at 49 magnification and merged using BZ-II Analyser Software. Then, the regions of interest were cut out and analysed using the Hybrid Cell Count of the BZII Analyser Software. Settings of brightness and threshold were adapted and applied for all measurements. The threshold was set to identify astrocyte clusters. To determine the covered area as a whole, the picture was re-analysed with the threshold reduced to a minimum to include the whole area. 
RNA isolation and quantitative RT-PCR
Statistical analysis
Data are presented as the mean of the samples and standard deviation as standard error of the mean (SEM). Statistical analysis was performed using the SigmaPlot 11.0 software (Systat Software Inc.) using one-way ANOVA analysis with a P-value < 0.05, San Jose, California, USA (*), P < 0.01 (**) and P < 0.001 (***) considered statistically significant.
Results
Confirmatory tests (MSC profile & delivery to brain)
Prior to transplantation, MSCs were characterized by flow cytometry for MSC-specific marker expression and differentiation potential. Mouse-derived MSC showed positive expression for typical MSC markers CD44 and CD90 and negative expression for CD11b and CD45 as well as their ability to differentiate into osteoblasts, adipocytes and chondrocytes (see Supplement). Up to 28 days after transplantation, GFP + -MSC were observed in hippocampus and cortex ( Figure 1 ; Figure S5 ). In addition to the MSC found in the brain, MSC were observed in bone marrow, lung and liver (manuscript in preparation). GFP + MSC were found mainly around Aß plaques and seemed to be integrated into the corona of resident microglia surrounding these plaques. We did not observe transplant-related acute toxicity or adverse events.
Amyloid content
We found no transplant-related changes in total amyloid-b content as measured by thioflavin-S staining of plaques at different sizes. However, we did observe changes in the pyroglutamate-beta amyloid (pE3-Ab) sub-component of amyloid b plaques at day 28 ( Figures 2 and 3) . When pE3-Ab plaques are categorized as small (<50 lm), medium (50-100 lm) and large (>100 lm) as described by Kim et al. [7] , we found a treatment-related increase in the number of small size plaques, but decrease in medium size plaques in the hippocampus on day 28 ( Figure 2C ). No changes were observed in the cortex on day 28 ( Figure 2B ) and on day 7 ( Figure 3A , left).
Histology
The following observations were made in histological analysis: Transplanted MSC (derived from GFPtransgenic mice) were found in and around amyloid plaques (Figure 1 ; Figure S5 ). A lower amount of pE3-Ab was found within vessels of the MSC-treated group compared to controls ( Figure 3B ). In addition, we observed pE3-Ab accumulation in large astrocytes with processes ( Figure 3C ). These cells were mainly seen around amyloid plaques and a reduction in the presence of these processes-bearing astrocytes was observed in the MSC-treated group compared to controls. We observed in the histological analysis variability between the different animals transplanted with MSC and controls indicating that even when all mice were close in age they behave independently.
MSC transplantation effect on microglia
It is known that MSC exert anti-inflammatory effects. We therefore examined whether APP/PS1 mice receiving MSC-transplants showed a reduced microglia activation measured by microglia size, represented by Iba-1-covered area. Quantitative analysis showed that the total area occupied by Iba-1-positive microglia was significantly decreased in hippocampus and cortex of mice treated with MSC compared to NaCl at day 28 ( Figure 4D ). No significant differences were observed by day 7 in the hippocampus but were seen in the cortex ( Figure S3D ). Microglia numbers were significantly reduced in the cortex but not in the hippocampus of the MSC-treated group compared to controls after 28 days ( Figure 4B ). No significant change was observed after 7 days ( Figure S3B ). We observed that in mice receiving MSC that microglia were more regularly distributed in comparison to the more clustered distribution in the control group (Figure 4A,C; Figure S3A,D) . In addition, morphological changes were observed after transplantation. In MSC-treated mice, microglia were more ramified with more processes per cell ( Figure 4C inserts) .
MSC transplantation effect on astrocytes
In addition to microglia we wanted to examine whether transplanted MSC exert an effect on astrocyte activation. The analysis revealed changes in astrocytes distribution/area after treatment with MSC compared to NaCl controls. We saw a reduction in GFAP covered area after 7 days; this effect was somewhat deregulated by day 28 ( Figure S4 ).
MSC effect on gene expression: inflammation, neurogenesis, chemotaxis
Inflammation Expression of TNF-a was reduced in the cortex and hippocampus of the transplant group compared to controls. IL-6 was reduced in the hippocampus only and no effect was found for IL-10 and IFN-c (Figures 5 and 6 ). IL-6 expression was reduced in the hippocampus but not in the cortex. Expression level of PTGER2 was reduced in the cortex but elevated in the hippocampus of MSC transplanted animals compared to controls.
Neurogenesis/Trophic factors Expression of NGF was reduced in the cortex but not in the hippocampus of the transplant group compared to NaCl controls. No transplant-related changes were observed in either brain region for BDNF expression levels or for the angiogenesis gene VEGF-A (Figure 6 ).
Chemotaxis Expression of MCP-1 was reduced in the cortex and hippocampus of the transplant group compared to NaCl controls. No changes were observed for CCR5 levels.
Discussion
The role of neuroinflammation in the pathological progression of AD has been widely discussed [22, 23] as well as the pro-inflammatory reaction of microglia triggered by Ab. In this study, we used the transgenic APP/PS1 mouse model where amyloid plaques appear around week six and a full Ab pathology by 8 months [19] . The age of the recipient animals used in this study ranged from 13 to 15 months. In comparison to other AD mouse models the APP/PS1 mouse strain shows a stronger microgliosis, mimicking human microglial activation observed in AD [19] .
Injection of MSC into the tail vein appeared safe and effective: the GFP + MSC could be observed around Ab plaques and were seen to settle between the microglial cells. This clearly indicates the potential of MSC to migrate not just towards the brain but to sites of inflammation therein. Second, we demonstrated that one single treatment with systemically transplanted MSC leads to obvious changes in Aß pathology.
Recently, a study showed in the APP Tg2576 mouse model that human adipose stem cells labelled with magnetic nanoparticles reached the site after 1 day [24] . Another group reported survival of transplanted GFP + MSCs into a (PLP)-a-SYN mouse model of multiple system atrophy after 4 weeks of transplantation in substantia nigra and brainstem [25] . Our experiments 
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MSC -d28 NaCl -d28 document the presence of the transplanted MSC in the brain parenchyma within 4 weeks of delivery. In contrast to the direct access to the brain via stereotactic injection, systemic delivery of MSC via tail vein injection appeared safe and effective. Transplanted GFP + MSC were observed around Ab plaques and seemed to be integrated into the corona of microglia surrounding the Aß deposits, which clearly indicates the potential of MSC to migrate not just towards the brain but in addition they are attracted to other sites of inflammation therein. This, on the other hand, reveals a putative involvement in neuro-inflammatory processes.
There are three other groups studying the use of MSCs in mice as a potential therapy set up for Alzheimer's [17, [26] [27] [28] [29] , however, most of these studies used either intracranial transplantation of MSCs or used human MSCs. They also showed a reduction in amyloid plaques after day 7 [28] . The effect was no longer observed after 28 days indicating a short term effect of transplanted MSCs independent of the transplantation method. However, previous studies have accomplished amyloid plaque reduction through either multiple rounds of MSC transplantation or higher concentration of MSCs [8, 16, 17, [30] [31] [32] . Systemic MSC transplantation has only been tested in very young AD mice (4 months) when the mice had not fully developed the Alzheimer pathology [31] . Another study investigating systemic MSC transplantation did this for 6.5 months every 2 weeks for 2 months following and NaCl (n = 5). Statistical significances are represented as *P < 0.05, **P < 0.01 and ***P < 0.001.
monthly applications starting at age of 7 months [30, 31] . In none of the publications was a single application of MSCs tested to demonstrate the efficiency. AD is characterized by the presence of increased levels of pro-inflammatory cytokines [33] mainly produced by aged microglia and astrocytes [34] . Here, we sought to explore the effect of MSC transplantation on general expression levels of genes related to inflammation, neurogenesis and chemotaxis.
The fact that at each time point analysed some factors showed no transplant-related changes in gene expression, inflammation (IL-10, IFNc), neurogenesis (VEGF-A, BDNF), chemotaxis (CCR5) indicates clearly that the effects of MSCs are not ubiquitous or necessarily on a broad spectrum and require a differentiated analysis.
Yet in other respects, effects were found at each time point observed. Most notably in the neuroinflammation group, we observed a transplant-related reduction in TNF-a gene expression which is known to have a prominent role in AD disease progression maybe even initiating pathological changes [35, 36] . The increasing expression of TNF-a in the cortex was shown in a triple transgenic AD mouse model at early prepathological time points, correlating with enhanced activation of microglia [37] . In this mouse model, inflammatory changes also correlate with cognitive deficits and synaptic dysfunction [38, 39] and overexpression of TNF-a made a major contribution to neuronal death [40] , whereas inhibition of TNF-a in an AD mouse model resulted in lower amyloid beta levels and cognitive impairment [41] . In line with our findings, Kim et al. 2013 could also show down-regulation of TNF-a up to 12 weeks after intravenous administration of human amniotic (placenta derived) stem cells in an APPswe (Tg2576) Alzheimer mouse model [7] , others have demonstrated similar effects after intracranial application of MSCs [17, 42, 43] . Less pronounced than for TNF-a, expression level of IL-6, another pro-inflammatory cytokine, was also reduced in the hippocampus but not in the cortex.
In the neurogenesis group, we found MSC transplantation associated with a reduction in NGF expression. Perhaps surprisingly this could be construed as having a potential therapeutic benefit. While NGF supports survival, regulation and differentiation of neurones and neuronal stem cells [44] , it is also associated with disturbed neurogenesis in AD [45] [46] [47] . High NGF levels result in impaired neocortical choline acetyl transferase (ChAT) activity which is linked to dementia and might be correlated with the memory loss observed in AD [48, 49] . A reduction in NGF correlates with changes in microglial morphology and distribution. It is known that reactive microglia encourage pro-NGF expression resulting in detrimental effects [50] . Since we analysed the NGF expression on mRNA level, we did not distinguish between pro-NGF and mature NGF. Pro-NGF is elevated in AD patients [44] and is normally produced by microglia. The pro-NGF in AD is impaired [51] and subsequently induces apoptosis in neurones. Hence, the reduction on the expression level of NGF in this study could be beneficial in regard to a lower level of proNGF.
The most direct indication of the complexity of MSC immune-modulatory effects is exemplified by our findings for prostaglandin E2 receptor (PTGER2), a proinflammatory factor, highly elevated in AD patients and implicated in AD progression [52, 53] . PTGER2 can be neurotoxic [54] , but on the other hand PTGER2 signalling is implicated for its potential role in longterm synaptic plasticity and cognitive function [55] . The observed MSC-related decreased expression of PTGER2 in the cortex while increased in the hippocampus requires further study.
During AD, MCP-1 expression is increased, attracting monocytes and microglia which account for pathologi- cal gliosis in AD [56] . Here, we show that transplanted MSCs are able to down-regulate MCP-1 levels -and a corresponding reduction in microglial numbers at least in the hippocampus was observed. Others in this field have observed a transplant-related increase in microglial levels [57] or no change over time [7] .
While the number of microglia may not be a good indicator of potential therapeutic action, changes in activation status might be more significant. Microglia exist in many different activation states [58] . Aggregated Ab is known to induce microglial activation [59] . In this context, we find a transplant-associated reduction in large-sized microglia which are deemed indicative of an activated state [60] . Such an effect was also found by Kim et al. [31] following systemic injection of placenta derived hMSC into APPswe (Tg2576) AD mice. The group observed an initial increase in microglial size, later followed by a size reduction, indicating that any studies into the immune-modulatory and antiinflammatory dynamics of transplanted MSC are very time point dependent. This is also demonstrated by our observations shown in the supplementary data. Ultimately, to use the immune-modulatory properties of MSCs for therapeutic purposes, the long-term effects on AD disease progression will need to be investigated as well as the benefits of follow-up transplantation of MSC.
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